Stoppage of US funds likely to lead to more than 4mn AIDS deaths, says UN
The report, however, highlighted the remarkable efforts of communities and governments that have been key in bringing down the numbers of new HIV infections by 40% and AIDS-related deaths by 56% since 2010 – before the sudden stoppage of the US funding six months back triggered a crisis in global AIDS response.
'This is not just a funding gap – it's a ticking time bomb,' said UNAIDS Executive Director Winnie Byanyima. 'We have seen services vanish overnight. Health workers have been sent home. And people – especially children and key populations – are being pushed out of care.'
The 2025 Global AIDS Update, AIDS, Crisis and the Power to Transform report said a historic fund crunch is threatening to unravel decades of progress unless countries can make radical shifts in HIV programming and funding.
'Despite marked progress in the HIV response in 2024, the weakening aid consensus, and significant and abrupt funding shortfalls in the HIV response in 2025 have triggered widespread disruption across health systems and cuts to frontline health workers has halted HIV prevention programmes, jeopardising HIV treatment services,' the report said.
'In time of crisis, the world must choose transformation over retreat,' Byanyima said. 'Together, we can still end AIDS as a public health threat by 2030 – if we act with urgency, unity, and unwavering commitment.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
an hour ago
- The Print
UNAIDS 2025 report warns of funding gaps in fight against HIV as India battles stigma, discrimination
Also, in India, more than 80 percent of surveyed women aged between 15 and 49 years were reported between 2020 and 2024 to lack autonomy over their sexual choices and reproductive healthcare. Additionally, over 90 percent of them lacked information about contraceptive use. The report titled 'AIDS, Crisis And The Power To Transform', released on 10 July, also highlights that the prevalence of intimate partner violence among partnered or married women living with HIV in the same age group in India stood at 24 percent—just 10 percent less than Liberia, where the prevalence was found to be highest globally. The figures are based on data from 2020-2024. New Delhi: The 2025 Global AIDS Update by UNAIDS (Joint United Nations Programme on HIV/AIDS) shows that 30 percent of people surveyed in the 15-49 age group in India reported facing HIV-related stigma and discrimination. The 2025 update notes the impact that massive funding cuts by international donors are having on countries most affected by HIV, and how the threat of a funding crisis may hurt global progress in the fight against HIV/AIDS unless countries alter their programming. According to the UNAIDS Executive Director Winnie Byanyima, the Global HIV response shows a decline of newly HIV infected persons by 40 percent, and of 56 percent deaths since 2010. However, the withdrawal of the US President's Emergency Plan for AIDS Relief (PEPFAR), the biggest contributor to global response, may lead to 6 million additional people being infected, and an additional 4 million deaths by 2029. The funding crisis has disrupted treatment and prevention programmes around the world, the report says. But it also points to the emergence of new prevention tools, like Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP), 'which has shown near-complete efficacy in clinical trials'. It can prevent HIV with injection doses twice a year. The manufacturer of Lenacapavir, Gilead Sciences, has licenced six generic manufacturers, of which Dr Reddy's Laboratories, Emcure, Hetero, and Mylan—subsidiary of Viatris—operate in India. However, affordability and access are still big challenges. According to the report, in terms of region-wise distribution, Eastern and Southern Africa saw the highest new HIV infections in 2024 at 37 percent, the lowest being in the Caribbean at one percent. In Asia and the Asia Pacific, of which India is a part, the figure stands at 23 percent. With respect to people living with HIV in 2024, the highest was reported in Eastern and Southern Africa at 52 percent, or 21.1 million. The lowest number of people was in the Caribbean—one percent, or 3,40,000. In Asia and Asia Pacific, the number was 17 percent, or 6.9 million. India is among the 13 of the 35 reporting countries that have reached safe injecting targets—90 percent using sterile equipment at last injection. It is clubbed with South Africa, Thailand and Brazil under Low-Dependency Countries in the matrix of dependency on PEPFAR funding. The report also mentions that social enterprises help diversify revenue resources. In India, the Mist LGBTQ Foundation runs an online platform to market merchandise, and offer HIV self-testing and PrEP consultations, either free or at a low rate. Another organisation, the Network of Maharashtra People Living with HIV TAAL+ Pharmacy sells antiretroviral and other medicines at discounted prices via corporate social responsibility partnerships. (Edited by Mannat Chugh) Also Read: Bringing dramatic drop in TB deaths, how TN set an example for rest of India with one-of-a-kind model
Time of India
8 hours ago
- Time of India
US aid cuts halt HIV vaccine research in South Africa, with global impact
Johannesburg: Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine , and hopes were high for another step toward limiting one of history's deadliest pandemics. Then the email arrived. Stop all work, it said. The United States under the Trump administration was withdrawing all its funding. The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the world. Their research project, called BRILLIANT , was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere. But the $46 million from the U.S. for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home. South Africa hit hard by aid cuts South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the country's white Afrikaner minority. The country had been receiving about $400 million a year via USAID and the HIV-focused PEPFAR. Now that's gone. Glenda Grey, who heads the Brilliant program, said the African continent has been vital to the development of HIV medication, and the U.S. cuts threaten its capability to do such work in the future. Significant advances have included clinical trials for lenacapavir, the world's only twice-a-year shot to prevent HIV, recently approved for use by the U.S. Food and Drug Administration. One study to show its efficacy involved young South Africans. "We do the trials better, faster and cheaper than anywhere else in the world, and so without South Africa as part of these programs, the world, in my opinion, is much poorer," Gray said. She noted that during the urgency of the COVID-19 pandemic , South Africa played a crucial role by testing the Johnson & Johnson and Novavax vaccines, and South African scientists' genomic surveillance led to the identification of an important variant. Labs empty and thousands are laid off A team of researchers at the University of the Witwatersrand has been part of the unit developing the HIV vaccines for the trials. Inside the Wits laboratory, technician Nozipho Mlotshwa was among the young people in white gowns working on samples, but she may soon be out of a job. Her position is grant-funded. She uses her salary to support her family and fund her studies in a country where youth unemployment hovers around 46%. "It's very sad and devastating, honestly," she said of the U.S. cuts and overall uncertainty. "We'll also miss out collaborating with other scientists across the continent." Professor Abdullah Ely leads the team of researchers. He said the work had promising results indicating that the vaccines were producing an immune response. But now that momentum, he said, has "all kind of had to come to a halt." The BRILLIANT program is scrambling to find money to save the project. The purchase of key equipment has stopped. South Africa's health department says about 100 researchers for that program and others related to HIV have been laid off. Funding for postdoctoral students involved in experiments for the projects is at risk. South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research funding over the next five years due to the aid cuts, which affect not only work on HIV but also tuberculosis - another disease with a high number of cases in the country. Less money, and less data on what's affected South Africa's government has said it will be very difficult to find funding to replace the U.S. support. And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa's HIV program have already been laid off, the government has said. Also gone are the data collectors who tracked patients and their care, as well as HIV counselors who could reach vulnerable patients in rural communities. For researchers, Universities South Africa, an umbrella body, has applied to the national treasury for over $110 million for projects at some of the largest schools. During a visit to South Africa in June, UNAIDS executive director Winnie Byanyima was well aware of the stakes, and the lives at risk, as research and health care struggle in South Africa and across Africa at large. Other countries that were highly dependent on U.S. funding including Zambia, Nigeria, Burundi and Ivory Coast are already increasing their own resources, she said. "But let's be clear, what they are putting down will not be funding in the same way that the American resources were funding," Byanyima said.
Hindustan Times
8 hours ago
- Hindustan Times
Trump's budget cuts for US aid halt HIV vaccine research in South Africa
Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history's deadliest pandemics. Then the email arrived. The research project, called BRILLIANT, was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere.(AP/Representational) Stop all work, it said. The United States under the Trump administration was withdrawing all its funding. The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the world. Their research project, called BRILLIANT, was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere. But the $46 million from the U.S. for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home. South Africa hit hard by aid cuts South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the country's white Afrikaner minority. The country had been receiving about $400 million a year via USAID and the HIV-focused PEPFAR. Now that's gone. Glenda Grey, who heads the Brilliant program, said the African continent has been vital to the development of HIV medication, and the U.S. cuts threaten its capability to do such work in the future. Significant advances have included clinical trials for lenacapavir, the world's only twice-a-year shot to prevent HIV, recently approved for use by the U.S. Food and Drug Administration. One study to show its efficacy involved young South Africans. 'We do the trials better, faster and cheaper than anywhere else in the world, and so without South Africa as part of these programs, the world, in my opinion, is much poorer,' Gray said. She noted that during the urgency of the COVID-19 pandemic, South Africa played a crucial role by testing the Johnson & Johnson and Novavax vaccines, and South African scientists' genomic surveillance led to the identification of an important variant. Labs empty and thousands are laid off A team of researchers at the University of the Witwatersrand has been part of the unit developing the HIV vaccines for the trials. Inside the Wits laboratory, technician Nozipho Mlotshwa was among the young people in white gowns working on samples, but she may soon be out of a job. Her position is grant-funded. She uses her salary to support her family and fund her studies in a country where youth unemployment hovers around 46%. 'It's very sad and devastating, honestly," she said of the U.S. cuts and overall uncertainty. 'We'll also miss out collaborating with other scientists across the continent.' Professor Abdullah Ely leads the team of researchers. He said the work had promising results indicating that the vaccines were producing an immune response. But now that momentum, he said, has 'all kind of had to come to a halt.' The BRILLIANT program is scrambling to find money to save the project. The purchase of key equipment has stopped. South Africa's health department says about 100 researchers for that program and others related to HIV have been laid off. Funding for postdoctoral students involved in experiments for the projects is at risk. South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research funding over the next five years due to the aid cuts, which affect not only work on HIV but also tuberculosis — another disease with a high number of cases in the country. Less money, and less data on what's affected South Africa's government has said it will be very difficult to find funding to replace the U.S. support. And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa's HIV program have already been laid off, the government has said. Also gone are the data collectors who tracked patients and their care, as well as HIV counselors who could reach vulnerable patients in rural communities. For researchers, Universities South Africa, an umbrella body, has applied to the national treasury for over $110 million for projects at some of the largest schools. During a visit to South Africa in June, UNAIDS executive director Winnie Byanyima was well aware of the stakes, and the lives at risk, as research and health care struggle in South Africa and across Africa at large. Other countries that were highly dependent on U.S. funding including Zambia, Nigeria, Burundi and Ivory Coast are already increasing their own resources, she said. 'But let's be clear, what they are putting down will not be funding in the same way that the American resources were funding," Byanyima said.
